[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614753":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":58,"collaborators":22,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":22,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":22,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":44,"whyStopped":22,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"neoadjuvant serplulimab","EXPERIMENTAL","serplulimab in combination with weekly paclitaxel and carboplatin as neoadjuvant therapy",[13,14,15],"Drug: Serplulimab","Drug: Paclitaxel","Drug: Carboplatin",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Serplulimab","1.5mg\u002Fkg qw, start from C1D15",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Paclitaxel","80mg\u002Fm\\^2 qw",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Carboplatin","AUC=1.5, D1, 8, 15, every 28 days",[9],[32],{"name":33,"affiliation":34,"role":35},"Wenjin Yin, M.D.","Renji Hospital,School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":22,"email":40},"CONTACT","86(21)68385569","yinwenjin@renji.com",[42],{"facility":43,"status":44,"city":45,"state":22,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56],{"name":33,"role":38,"phone":57,"phoneExt":22,"email":40},"86(21)58852345",{"type":35,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Wenjin Yin","Deputy Chief of Breast Surgery Department","100614753","phase-2-neoadjuvant-serplulimab-plus-weekly-paclitaxel-and-carboplatin-in-tnbc-neo-serpent-100614753",false,"NCT07283692","Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","NEOadjuvant SERplulimab Plus Weekly PaclitaxEl and carboplatiN in Triple-negative Breast Cancer: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Trial","Inclusion Criteria:\n\n* Female, Aged ≥18 and ≤70 years\n* Histologically confirmed triple negative breast cancer (ER\\\u003C10%, PR\\\u003C10%, and HER2 negative)\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period","FEMALE","18 Years","70 Years",{"count":72,"type":73},46,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.",[79],"Triple Negative Breast Cancer",[81,82,83],"breast cancer","neoadjuvant","serplulimab","2026-05-10",{"date":86,"type":87},"2026-05-13","ACTUAL",{"date":89,"type":87},"2026-03-01",{"date":91,"type":73},"2031-09",{"name":5,"class":6},1]